Latest1 information on COVID-19
©2022 Stanford Medicine
Not Recruiting
Trial ID: NCT04260698
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Inclusion Criteria:
- Patients must be at least 12 years of age
- Applicable disease criteria
- Patients must have one or two partially HLA-matched CBUs
- Back-up stem cell source
- Sufficient physiological reserves
- Females of childbearing potential agree to use appropriate method of contraception
- Signed written informed consent
Exclusion Criteria:
- Extensive bone marrow fibrosis
- Donor specific anti-HLA antibodies
- Pregnancy
- Medically unsuitable for transplant
biological: omidubicel
Not Recruiting
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Khanh Nguyen
650-721-2372